New Nasal Vaccine Booster Protects Lungs for 6 Months

A revolutionary nose spray vaccine could change how we fight respiratory viruses, offering six months of robust protection with a single dose.

Researchers at the National University of Singapore and Monash University created Clec9AOMNI, an intranasal vaccine booster that outperforms traditional mRNA shots. Published in The Journal of Clinical Investigation, the study shows the spray delivers powerful protection right where viruses enter the body: the nose and lungs.

The science behind the breakthrough is elegant. The team fused antibodies that target dendritic cells (immune system coordinators) with proteins from COVID-19 variants and the original SARS virus. When sprayed into the nose, this combination trains the immune system exactly where protection matters most.

The results speak volumes. Animals given the nasal booster three months after their initial COVID vaccination showed significantly stronger immune responses than those receiving traditional booster shots. Six months later, the nasal spray group still maintained robust protection. When exposed to the virus, researchers found undetectable viral levels in their lungs and nasal passages.

Current COVID vaccines face three major limitations: immunity fades within months, they don't protect the nose and throat well, and they offer limited coverage against coronavirus cousins beyond COVID-19. The nasal spray tackles all three challenges at once.

Associate Professor Sylvie Alonso, who led the study, explained the game-changing advantage. Existing vaccines prevent severe disease but lose effectiveness against infection within months because they generate little immunity at mucosal surfaces. The intranasal approach changes that equation entirely.

The Ripple Effect

This innovation extends beyond COVID-19. The Clec9A platform works by targeting specific immune cells present in humans, meaning the technology could adapt to fight other respiratory infections. The harsh environment inside the nose typically breaks down vaccines quickly, but this delivery system solves that problem.

The breakthrough offers special promise for elderly people and others who struggle with traditional injections. Nasal administration is painless, needle-free, and potentially more effective for vulnerable populations who need protection most.

The research team now plans to validate their findings for human use, ensuring the approach translates to human anatomy and immune responses. Beyond coronavirus protection, they're exploring applications for other infectious diseases that enter through the respiratory tract.

Fewer booster shots, stronger protection, and a simple spray instead of needles: this could be the future of keeping communities healthy.